1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,800 | 4,100 | 23.12. | |
| 3,840 | 4,020 | 23.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| KEYMED BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| Mo | Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis | 154 | PR Newswire | CHENGDU, China, Dec. 23, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved... ► Artikel lesen | |
| Mo | KEYMED BIO-B (02162): VOLUNTARY ANNOUNCEMENT NMPA APPROVED THE SNDA OF STAPOKIBART FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS | 2 | HKEx | ||
| 16.12. | KEYMED BIO-B (02162): CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG | 2 | HKEx | ||
| 09.12. | KEYMED BIO-B (02162): VOLUNTARY ANNOUNCEMENT THE LATEST DATA FROM THE PHASE I/II CLINICAL STUDY OF CM336 AT THE 66TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ... | 1 | HKEx | ||
| 23.09. | KEYMED BIO-B (02162): 2024 INTERIM REPORT | - | HKEx | ||
| 13.09. | China NMPA approves Keymed Biosciences' Stapokibart for atopic dermatitis | 1 | Pharmaceutical Business Review | ||
| 12.09. | Keymed: Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults | 271 | PR Newswire | CHENGDU, China, Sept. 12, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved... ► Artikel lesen | |
| 12.09. | KEYMED BIO-B (02162): INSIDE INFORMATION ANNOUNCEMENT STAPOKIBART WAS GRANTED MARKETING APPROVAL FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR THE ... | 1 | HKEx | ||
| 28.08. | Keymed Biosciences Announces Interim Results for First Half of 2024 | 252 | PR Newswire | CHENGDU, China, Aug. 28, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced its interim results for the first half of 2024, along with a corporate update.
Rapid... ► Artikel lesen | |
| 27.08. | KEYMED BIO-B (02162): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024 | - | HKEx | ||
| 15.08. | KEYMED BIO-B (02162): DATE OF BOARD MEETING | - | HKEx | ||
| 09.07. | KEYMED BIO-B (02162): INSIDE INFORMATION - EXCLUSIVE LICENSE AGREEMENT FOR CM512 AND CM536 | 1 | HKEx | ||
| 21.06. | Keymed Biosciences gibt Ergebnisse zur Sicherheit und Wirksamkeit von CM313 bei primärer Immunthrombozytopenie bekannt, die im NEJM veröffentlicht wurden | 186 | PR Newswire | CHENGDU, China, 21. Juni, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) gab heute bekannt, dass das Team um Lei Zhang/Renchi Yang vom Institut für Hämatologie der Chinesischen Akademie... ► Artikel lesen | |
| 20.06. | Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM | 287 | PR Newswire | CHENGDU, China, June 20, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced that Lei Zhang/Renchi Yang's team from the Institute of Hematology, Chinese Academy of... ► Artikel lesen | |
| 03.06. | Keymed Biosciences gibt Langzeit-Wirksamkeits- und Sicherheitsdaten aus einer klinischen Phase-III-Studie mit Stapokibart zur Behandlung von mittelschwerer bis schwerer atopischer Dermatitis bekannt | 84 | PR Newswire | CHENGDU, China, 3. Juni 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) gab heute bekannt, dass die langfristigen Wirksamkeits- und Sicherheitsdaten einer klinischen Phase-III-Studie... ► Artikel lesen | |
| 03.06. | Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis | 477 | PR Newswire | CHENGDU, China, June 3, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the long-term efficacy and safety data of a Phase III clinical trial of stapokibart injection... ► Artikel lesen | |
| 28.03. | Keymed Biosciences gibt Jahresergebnis 2023 und aktuelle Geschäftszahlen bekannt | 85 | PR Newswire | Einreichung eines Zulassungsantrags für Stapokibart (CM310) für die Behandlung von mittelschwerer bis schwerer Alzheimer-Krankheit bei Erwachsenen. Die NDA wurde von der chinesischen NMPA akzeptiert... ► Artikel lesen | |
| 26.03. | Keymed Biosciences Announces 2023 Annual Results and Business Updates | 294 | PR Newswire | Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the treatment of moderate-to-severe AD in adults. The NDA was accepted by the China's NMPA and granted priority review.Advanced... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 35,110 | +0,92 % | Tempus AI (NASDAQ:TEM) Shares Down 5.7% Following Insider Selling | ||
| RECURSION PHARMACEUTICALS | 7,310 | +0,97 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| HUMACYTE | 5,100 | +13,08 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen | |
| SCISPARC | 0,515 | +132,64 % | SciSparc Says AutoMax Receives First Delivery Of Vehicles From Jianghuai Automobile | ||
| QUANTUM-SI | 1,550 | +19,23 % | Quantum-Si präsentiert ProteoVue-Software für Proteinforschung | ||
| ADMA BIOLOGICS | 17,635 | +1,29 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| JANUX THERAPEUTICS | 55,59 | -0,98 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| VERA THERAPEUTICS | 41,960 | +0,10 % | Vera Therapeutics CEO Fordyce Marshall verkauft Aktien im Wert von 753.679 US-Dollar | ||
| SUMMIT THERAPEUTICS | 18,970 | -0,16 % | Where Will Summit Therapeutics Be in 5 Years? | ||
| STRUCTURE THERAPEUTICS | 29,620 | +4,85 % | Structure Therapeutics Inc.: Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer | SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| COEPTIS THERAPEUTICS | 0,208 | +46,27 % | Coeptis Therapeutics, Inc.: Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies | Coeptis Aims to Bring AI Innovation in Biotechnology and Technology
WEXFORD, Pa., Dec. 26, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq:... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 31,240 | -0,35 % | What 8 Analyst Ratings Have To Say About Avidity Biosciences | ||
| ARS PHARMACEUTICALS | 10,945 | -4,08 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Announces neffy (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies | ||
| ARCUTIS BIOTHERAPEUTICS | 15,040 | +0,33 % | Arcutis Biotherapeutics, Inc.: Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis | ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trialsRoflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 37,110 | +0,82 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors... ► Artikel lesen |
Das Unternehmen KEYMED BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,800 Euro und damit -2,56 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KEYMED BIOSCIENCES INC finden Sie auf Wallstreet Online.
